Aytu biopharma reports fiscal 2024 full year and fourth quarter operational and financial results

Full year fiscal 2024 consolidated net revenue of $81.0 million; rx segment net revenue of $65.2 million full year fiscal 2024 adhd portfolio net revenue up 23% compared to fiscal 2023 full year fiscal 2024 adjusted ebitda1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023 $20.0 million cash balance at june 30, 2024 company expects rx segment net revenue and adjusted ebitda growth in fiscal 2025 from current levels company to host conference call and webcast today, september 26, 2026, at 4:30 p.m. eastern time denver, co / accesswire / september 26, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2024 full year and fourth quarter.
AYTU Ratings Summary
AYTU Quant Ranking